Nichd: r & d: to evaluate in obese and non-obese women the pharmacokinetics (PK), pharmacodynamic (PD) effects, safety, and contraceptive efficacy of levonorgestrel butanoate (LB) formulated as a…
Active Awarded Last action
- Contract number
- 75N94025F00001
- Awardee
-
Oregon Health & Science University UEI NPSNT86JKN51
- Awarding agency
-
National Institute of Child Health and Human Development
National Institutes of Health, Department of Health and Human Services
- Obligated
- $543,457
Award facts
- Contract value 85% obligated
-
- $543,456.76 Current, with exercised options
- $641,267.76 Potential, with all options
- Completion date 33% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 18 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Portland, OR 97239, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $445,690 | |
| Other Administrative Action | $0 | |
| Original award | $97,767 |
About this award
The National Institute of Child Health and Human Development (NICHD) awarded a delivery order valued at $641,267.76 to Oregon Health & Science University (OHSU) on August 1, 2025, with completion targeted for March 31, 2029. This research and development effort will evaluate the pharmacokinetics, pharmacodynamic effects, safety, and contraceptive efficacy of levonorgestrel butanoate (LB), a long-acting injectable contraceptive, in both obese and non-obese women. The contract is structured as a cost-no-fee delivery order with no set-aside designation, indicating competitive selection through an existing indefinite delivery contract vehicle. OHSU, a prominent academic medical center and state-controlled institution of higher learning based in Portland, Oregon, will perform the work at its Portland facility.
OHSU brings substantial relevant experience to this engagement, having previously contracted with NICHD for central laboratory services supporting contraceptive efficacy studies and maintaining an extensive portfolio of NICHD grant funding focused on contraceptive development and efficacy evaluation. The institution's demonstrated expertise in conducting advanced medical research, biostatistical analysis, and specialized clinical services positions it well to execute this pharmacokinetic and safety evaluation study. This contract represents a continuation of the agency's strategic investment in contraceptive research and development through established academic research partnerships.
Description
Nichd: r & d: to evaluate in obese and non-obese women the pharmacokinetics (PK), pharmacodynamic (PD) effects, safety, and contraceptive efficacy of levonorgestrel butanoate (LB) formulated as a long-acting injectable: non-severable
Quick answers
Who was awarded contract 75N94025F00001?
75N94025F00001 was awarded to Oregon Health & Science University by National Institute of Child Health and Human Development (National Institutes of Health) on August 1, 2025.
How much is contract 75N94025F00001 worth?
The government has obligated $543,457 on 75N94025F00001. Its potential value, with all options, is $641,268.
Is contract 75N94025F00001 an order under another contract?
Yes. 75N94025F00001 is a delivery order under 75N94020D00016, an indefinite delivery contract.
Was contract 75N94025F00001 competed?
The extent of competition for 75N94025F00001 was full and open competition. The government received 18 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award